List of Excipients in Branded Drug CALCITRIOL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	BUTYLATED HYDROXYANISOLE
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	BUTYLATED HYDROXYTOLUENE
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	COCONUT OIL
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	FD&C YELLOW NO. 6
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	GLYCERIN
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	SORBITOL
Aphena Pharma Solutions - Tennessee LLC	CALCITRIOL	calcitriol	43353-138	TITANIUM DIOXIDE

Generic Drugs Containing CALCITRIOL

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	BUTYLATED HYDROXYANISOLE
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	BUTYLATED HYDROXYTOLUENE
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	COCONUT OIL
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	FD&C YELLOW NO. 5
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	FERROSOFERRIC OXIDE
Hikma Pharmaceuticals USA Inc	calcitriol	0054-0007	GELATIN

What are the Most Frequently-Used Excipients in CALCITRIOL?

# Of NDCs	Excipient
1	ALCOHOL
5	AMMONIA
4	BUTYL ALCOHOL
42	BUTYLATED HYDROXYANISOLE
42	BUTYLATED HYDROXYTOLUENE
1	CI 45430
1	CI 77891

# Calcitriol Excipient Strategy and Commercial Opportunities in Oral, Injectable, and Topical Formulations

Last updated: August 4, 2026

Calcitriol is a high-potency vitamin D3 analog with limited aqueous solubility, sensitivity to light and oxidation, and a narrow therapeutic margin because excessive exposure can cause hypercalcemia and hypercalciuria. The strongest commercial opportunities are differentiated low-dose oral systems, stable topical products, preservative-controlled liquid formulations, and specialized injectable presentations for renal disease. Since the active ingredient is long established, value is more likely to come from formulation performance, dose accuracy, manufacturing controls, regulatory execution, and market access than from new-molecule exclusivity.

What excipient properties are required for calcitriol formulations?

Calcitriol requires excipients that maintain chemical stability, support uniform microgram-level dosing, and control exposure. The formulation strategy differs by route.

Formulation challenge	Commercial consequence	Preferred excipient strategy
Very low dose	Content-uniformity risk	Dilution in a homogeneous liquid vehicle, controlled mixing, low-adsorption packaging
Poor water solubility	Limits conventional aqueous tablets and solutions	Lipid vehicles, cosolvents, surfactants, or self-emulsifying systems
Light sensitivity	Potency loss during manufacture and storage	Opaque packaging, light-protective secondary packaging, antioxidant systems
Oxidation risk	Degradation and impurity formation	Low-oxygen headspace, antioxidants, oxygen-barrier containers
Narrow therapeutic margin	Safety risk from dose variability	High-precision filling, validated assay and uniformity methods
Topical delivery	Need for local skin deposition with limited systemic exposure	Ointment, emulsion, gel, foam, or anhydrous lipid vehicle
Injectable use	Sterility and compatibility requirements	Parenteral-grade cosolvents, surfactants, antioxidants, and container closure systems

Calcitriol is generally handled as a potent, low-dose active rather than as a conventional bulk powder. Process controls and excipient selection must prevent segregation, adsorption to equipment, and concentration gradients.

What excipients are used in approved calcitriol products?

Approved calcitriol products demonstrate that lipid and cosolvent systems are commercially viable. Product-specific inactive ingredients must be confirmed against the current FDA labeling and inactive ingredient records because formulations can change after manufacturing transfers or generic approvals.

Oral capsules and oral solutions

Rocaltrol oral products historically used lipid-based vehicles and capsule excipients appropriate for a highly potent, lipophilic active. Soft gelatin capsules are commercially attractive because they can contain a pre-dissolved or uniformly dispersed dose in a nonaqueous vehicle. Typical formulation concepts include:

• Medium-chain or fractionated triglycerides
• Other pharmaceutical lipid vehicles
• Gelatin and glycerin for softgel shells
• Antioxidants such as tocopherol derivatives where justified
• Colorants and opacifiers for dose identification and light protection
• Low-adsorption primary packaging

A lipid-filled softgel can reduce content-uniformity risk compared with a powder-filled hard capsule. It also supports small fill volumes and can improve patient acceptance for pediatric or dialysis-associated use.

An oral solution provides a different value proposition. It can support dose titration and administration to patients who cannot swallow capsules. The main risks are precipitation, adsorption to the bottle or dosing syringe, microbial control, and chemical degradation during repeated opening.

Injectable calcitriol

Calcitriol injection products, including Calcijex, require a sterile formulation compatible with intravenous administration. The excipient system must address solubilization without creating unacceptable toxicity, precipitation, particulate formation, or container interaction.

Commercially relevant excipient categories include:

• Water-miscible cosolvents
• Parenteral surfactants
• Antioxidants
• pH-adjusting agents
• Low-extractable container closure materials

Injectable products have a higher manufacturing burden than oral products because sterility assurance, particulate control, endotoxin limits, container closure integrity, and in-use handling are central to approval and hospital procurement.

Topical calcitriol

Vectical ointment contains calcitriol at a low concentration for topical use in plaque psoriasis. Topical systems can use anhydrous hydrocarbon bases, emulsion systems, gels, foams, or other vehicles that control skin deposition and spreadability.

The commercial formulation objective is not simply maximum penetration. Excessive dermal penetration can increase systemic exposure and calcium-related safety concerns. A competitive product should demonstrate:

• Consistent dose delivery per unit mass or actuation
• Acceptable skin feel and spreadability
• Uniform distribution of calcitriol throughout the vehicle
• Stability under temperature and light stress
• Controlled dermal deposition
• Low irritation potential
• Packaging that minimizes oxygen and light exposure

What formulation technologies offer the best commercial opportunities for calcitriol?

The strongest opportunities involve differentiated delivery rather than simple reformulation.

1. Low-dose lipid softgels

A modern softgel could compete on dose uniformity, stability, packaging, and manufacturing consistency. A small-volume fill containing dissolved calcitriol in a lipid vehicle may reduce the risk of segregation and improve batch uniformity.

Potential product advantages include:

• Multiple microgram strengths
• Unit-dose packaging
• Improved portability
• Reduced tablet burden
• Better suitability for patients requiring precise titration

The principal technical barriers are shell compatibility, oxygen permeability, migration of formulation components, long-term stability, and validated dissolution after storage.

2. Oral liquid with an integrated dosing system

A ready-to-use oral liquid could target patients with swallowing difficulty, pediatric patients, and individuals requiring fine dose adjustments. Commercial differentiation would depend on an accurate oral syringe or calibrated dispensing device.

The liquid should be assessed for:

• Dose homogeneity throughout shelf life
• Recovery from the bottle and syringe
• Adsorption to plastic components
• Microbial preservation
• Photostability
• Precipitation after temperature cycling
• Compatibility with feeding tubes if that use is pursued

The product should avoid a dosing architecture that makes administration errors likely. At microgram doses, a small volume mismatch can create clinically meaningful variation.

3. Self-emulsifying or nanoemulsion systems

Self-emulsifying drug delivery systems can improve apparent solubility and reduce precipitation after dilution in gastrointestinal fluids. These systems may use combinations of lipid, surfactant, and cosurfactant excipients.

Their commercial value depends on evidence that the system improves one or more of the following:

• Exposure consistency
• Food-effect control
• Dose proportionality
• Storage stability
• Manufacturing robustness
• Patient adherence

The regulatory burden increases if the formulation materially changes exposure. A bioequivalence program must be designed around the reference product and the pharmacokinetic behavior of calcitriol.

4. Topical foam, gel, or spray

A non-ointment topical format could create a patient-experience advantage. Foam and spray products may improve scalp or intertriginous application, while gels may provide faster drying and lower residue.

The highest-value development targets are likely:

• Scalp psoriasis
• Hair-bearing areas
• Large-area application
• Patients who avoid greasy ointments
• Combination topical regimens

A topical reformulation must control systemic absorption and demonstrate comparable or improved local activity. The excipient system also must avoid interactions with other topical products used in psoriasis care.

5. Hospital-ready injectable packaging

Injectable calcitriol can be differentiated through packaging and workflow rather than active-ingredient novelty. Opportunities include:

• Ready-to-use unit doses
• Reduced preparation steps
• Low-sorption syringes
• Improved light protection
• Longer refrigerated or room-temperature stability
• Barcoded packaging for dialysis-center workflows

Any such product must preserve sterility and chemical stability while meeting hospital requirements for preparation time, labeling, and compatibility.

What patents protect calcitriol formulations?

Calcitriol’s active-ingredient and early product protection are largely historical. The current commercial value of a new calcitriol product is more likely to depend on formulation, manufacturing, delivery-device, packaging, and method-of-use claims.

Potentially protectable subject matter includes:

• Specific lipid or self-emulsifying excipient ratios
• Stable calcitriol solutions
• Antioxidant and oxygen-control systems
• Topical vehicles that provide defined dermal deposition
• Low-sorption packaging
• Unit-dose delivery devices
• Combination products
• Specific dosing regimens or patient populations
• Manufacturing processes that improve content uniformity

A formulation patent needs a credible technical distinction. Broad claims covering calcitriol with a conventional lipid, solvent, or ointment base are vulnerable to written-description, enablement, obviousness, and anticipation challenges.

How strong is the patent estate for calcitriol?

The foundational patent estate is weak as a barrier to generic entry because calcitriol has been marketed for decades. A new estate can still be commercially useful if it protects a clinically relevant delivery advantage and is supported by comparative data.

Patent strength is highest where the sponsor can link the excipient system to:

• Unexpected stability
• A clinically meaningful pharmacokinetic profile
• Reduced variability
• Improved local-versus-systemic exposure
• A difficult-to-reproduce manufacturing process
• A device-dependent dosing system

Patent strength is lower for routine substitutions such as changing one conventional oil for another without evidence of an unexpected result.

When does calcitriol lose exclusivity?

Calcitriol’s original small-molecule exclusivity and early composition patents have expired or are no longer the primary commercial barriers in the United States. The FDA lists calcitriol products in conventional small-molecule pathways, not biologic reference-product pathways.

Product category	Representative product	Regulatory status	Current exclusivity profile
Oral capsule	Rocaltrol	FDA-approved prescription drug	Legacy product; generic competition exists
Oral liquid	Calcitriol oral solution products	FDA-approved or product-specific generic pathways	Depends on product-specific approval and listings
Injectable	Calcijex	FDA-approved prescription injection	Legacy injectable market with formulation and supply-chain barriers
Topical ointment	Vectical	FDA-approved topical product	Legacy product; competition depends on approved alternatives and market availability

FDA approval dates and product-specific patent listings should be checked in the current Orange Book and FDA labeling before making a launch or litigation decision. The Orange Book identifies approved products, therapeutic equivalence information, and listed patent information for applicable products. It does not create exclusivity where no unexpired listed patent or regulatory exclusivity remains.[1]

What is the Orange Book status of calcitriol products?

Calcitriol is generally subject to the abbreviated new drug application framework for small-molecule generics. The Orange Book is relevant for:

• Reference listed drug designation
• Therapeutic-equivalence codes
• Listed patents
• Patent certification requirements
• Generic approval status
• Exclusivity periods attached to specific products

A Paragraph IV certification may be relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. If the patent owner brings suit within the statutory period, FDA approval can be subject to a stay of up to 30 months under the Hatch-Waxman framework, subject to statutory exceptions.[2]

For an old active ingredient such as calcitriol, the principal Paragraph IV risk is more likely to involve a newer formulation, delivery system, or method-of-use patent than the molecule itself.

Which companies are challenging calcitriol products?

Generic competition for calcitriol has historically included multiple manufacturers across oral and injectable presentations. Product availability changes through discontinuations, supply interruptions, manufacturing transfers, and ANDA ownership changes.

Competitive review should distinguish among:

• Approved ANDA holders
• Commercially active suppliers
• Authorized distributors
• Contract manufacturers
• Compounding pharmacies
• Discontinued or unavailable products

The relevant commercial question is not the number of approved applicants alone. It is the number of suppliers with active manufacturing capacity, reliable API access, and distribution into the target channel.

What FDA regulatory pathway applies to a new calcitriol formulation?

A new formulation may proceed through an ANDA, 505(b)(2) application, or, in limited circumstances, a full new drug application.

ANDA pathway

An ANDA is appropriate where the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to a suitable reference product. A major change in excipient system, dosage form, release profile, or route may complicate the ANDA strategy.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a materially different dosage form, delivery system, formulation, or indication that relies partly on existing findings for calcitriol. This route can support differentiated products such as:

• New topical dosage forms
• Novel oral liquids
• Alternative injectable presentations
• New delivery devices
• Reformulations with clinically relevant exposure differences

The sponsor should expect a formulation-specific clinical and chemistry, manufacturing, and controls package. The extent of clinical work depends on the difference from the reference product and the proposed labeling.

Combination and device considerations

An oral syringe, metered topical actuator, or ready-to-administer injectable presentation can create device-related requirements. Device performance, human factors, extractables and leachables, and container closure data may become central to approval.

What manufacturing and intellectual-property barriers affect calcitriol commercialization?

The principal manufacturing barriers are precision and stability.

Content uniformity

Calcitriol doses are measured in micrograms. Liquid vehicles require validated mixing and filling controls. Powder systems require careful dilution and segregation control. Sampling plans must detect low-level concentration variation.

Stability

Development programs should evaluate:

• Assay and degradation products
• Light exposure
• Oxygen exposure
• Temperature cycling
• Humidity
• Container closure performance
• In-use stability
• Transport conditions

API and process controls

Calcitriol API should be controlled for potency, related substances, residual solvents, particle characteristics where relevant, and light exposure during handling. The manufacturing process should minimize hold times and uncontrolled exposure to heat, air, and light.

Packaging

High-value packaging options include:

• Amber glass
• Opaque high-barrier plastics
• Aluminum or foil overwraps
• Nitrogen-controlled headspace
• Unit-dose blisters
• Low-sorption syringes
• Light-resistant topical tubes or pumps

Packaging patents can supplement formulation patents, but they are most defensible when tied to measurable stability or dosing performance.

How does calcitriol compare with other vitamin D analogs?

Product	Active ingredient	Main use areas	Formulation opportunity
Calcitriol	Active vitamin D3 metabolite	CKD-related mineral metabolism, hypoparathyroidism, topical psoriasis	Precision oral liquids, lipid systems, topical delivery
Paricalcitol	Vitamin D analog	Secondary hyperparathyroidism	Injectable and oral products; lower-calcemic positioning
Doxercalciferol	Vitamin D analog prodrug	Secondary hyperparathyroidism	Oral solid and liquid formulation strategies
Alfacalcidol	Vitamin D analog prodrug	Mineral and bone disorders in selected markets	Geographic and formulation-specific opportunities
Calcipotriol	Topical vitamin D analog	Psoriasis	Foam, gel, combination, and scalp delivery

Calcitriol has strong pharmacologic activity but a narrower safety margin than some analogs. A successful formulation should therefore emphasize exposure control, dose accuracy, and patient usability rather than simply increasing absorption.

What revenue exposure and market opportunities exist for calcitriol?

The addressable market is divided among chronic nephrology, endocrinology, dermatology, hospital dialysis, and specialty pharmacy channels. Revenue potential depends on product format and reimbursement more than on API cost.

Higher-value commercial segments

• Oral products requiring dose titration
• Products for patients with swallowing difficulty
• Dialysis-center injectable supply
• Non-greasy topical products
• Unit-dose and adherence-oriented packaging
• Products with differentiated stability or storage requirements
• Markets where branded topical or liquid competition is limited

Lower-value segments

• Undifferentiated conventional capsules
• Products competing solely on API cost
• Formulations with no stability or usability advantage
• Products dependent on a narrow distribution channel without supply differentiation

A generic capsule can generate volume but faces price erosion. A 505(b)(2) formulation can support stronger pricing if it solves a documented administration or stability problem and secures enforceable formulation or method-of-use claims.

What generic launch risks exist for calcitriol?

Generic launch risk is moderate for conventional oral products and higher for differentiated formulations.

Key risks include:

1. Bioequivalence failure caused by lipid vehicle differences.
2. Dose nonuniformity at microgram strength.
3. Precipitation or adsorption in oral liquids.
4. Stability failure under light or oxygen stress.
5. Topical bioequivalence complexity.
6. Limited injectable manufacturing capacity.
7. Regulatory delay caused by formulation changes.
8. Paragraph IV litigation involving newer formulation patents.
9. Supply disruption from a limited API or sterile manufacturing base.
10. Price compression after multiple ANDA approvals.

For an innovator, the best defense is a layered estate covering formulation, process, packaging, device, and method of use. For a generic applicant, the main advantage is the long-established active ingredient and the availability of conventional dosage-form precedents.

What licensing deals are most relevant to calcitriol?

Calcitriol licensing opportunities are most credible where the licensor contributes a defensible delivery platform, manufacturing process, device, or regional commercial infrastructure.

Potential deal structures include:

• Regional licensing for topical or oral-liquid products
• Co-development of a 505(b)(2) formulation
• Technology licensing for self-emulsifying systems
• Contract manufacturing and supply agreements
• Hospital-channel distribution partnerships
• Licensing of metered topical delivery devices
• API supply agreements with stability and quality commitments

A license based only on the calcitriol molecule is unlikely to command strong economics because the active ingredient is established and generic. A license tied to clinical evidence, patent claims, regulatory history, or specialized manufacturing is more commercially durable.

What patent litigation and settlement risks affect calcitriol?

Litigation risk is concentrated in new formulation and delivery patents. A conventional calcitriol generic is more likely to face routine Hatch-Waxman issues than molecule-level patent litigation.

Potential disputes include:

• Paragraph IV challenges to formulation patents
• Invalidity challenges against obviousness-prone excipient claims
• Non-infringement disputes over concentration ranges
• Method-of-use litigation
• Device patent disputes
• Trade-secret claims involving manufacturing processes
• Supply and license disputes involving API or sterile filling

Settlement agreements may include delayed generic entry, authorized-generic provisions, manufacturing licenses, or geographic restrictions. Any settlement involving a listed patent or delayed entry must be assessed under the FTC and antitrust framework applicable to pharmaceutical agreements.

Key Takeaways

• Calcitriol is a low-dose, poorly water-soluble, light- and oxidation-sensitive active ingredient.
• Lipid softgels, oral liquids, topical non-ointment systems, and hospital-ready injectables offer the clearest formulation opportunities.
• Content uniformity, dose accuracy, stability, and packaging are central commercial differentiators.
• Original calcitriol exclusivity is historical; new commercial protection must come from formulation, process, device, packaging, or method-of-use claims.
• Conventional oral generics face price erosion, while differentiated products may support 505(b)(2) positioning and stronger pricing.
• There is no biosimilar pathway for calcitriol because it is a conventional small molecule, not a biologic.
• The most defensible patent estates connect excipient selection to unexpected stability, exposure control, dermal deposition, or manufacturing performance.
• FDA Orange Book, labeling, and patent records remain the controlling sources for product-specific exclusivity and Paragraph IV analysis.

FAQs About Calcitriol Excipient and Commercial Strategy

Can calcitriol be formulated in a conventional aqueous oral solution?

Calcitriol can be difficult to maintain in a simple aqueous system because of low water solubility and stability risks. A cosolvent, surfactant, lipid, or self-emulsifying system is generally more practical, subject to safety, precipitation, preservation, and bioequivalence requirements.

Which packaging is best for calcitriol products?

The best package depends on dosage form, but light-resistant, oxygen-barrier packaging with low drug sorption is generally preferred. Unit-dose blisters, amber glass, foil overwraps, and opaque dispensing systems can reduce degradation risk.

Is a calcitriol topical foam commercially attractive?

A topical foam can be attractive if it improves application to the scalp or hair-bearing skin and reduces the greasy feel associated with ointments. Its value depends on local deposition, systemic exposure control, stability, device performance, and reimbursement.

Can a calcitriol formulation obtain new regulatory exclusivity?

A differentiated formulation may qualify for product-specific regulatory exclusivity or patent protection depending on the application pathway, clinical data, and approved labeling. The active ingredient itself does not provide meaningful new-molecule exclusivity.

Does calcitriol have biosimilar competition?

No. Calcitriol is a small-molecule drug. Competition proceeds through generic and, for certain differentiated products, 505(b)(2) pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, 43rd edition. Center for Drug Evaluation and Research.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2009). Vectical ointment prescribing information. Galderma Laboratories, L.P.

5. U.S. Food and Drug Administration. (2011). Rocaltrol prescribing information. Hoffmann-La Roche Inc.

6. U.S. Food and Drug Administration. (2011). Calcijex prescribing information. Abbott Laboratories.

7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

8. National Center for Biotechnology Information. (2024). PubChem compound summary for calcitriol. National Library of Medicine.